Find Reports
Select Report Type
Reimbursement Review
Displaying 1251 - 1264 of 1264
Please scroll or swipe to the right to view the full content.
| Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|
| Tafinlar and Mekinist | dabrafenib and trametinib | Pediatric low-grade glioma with BRAF V600E | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0029-000 | |||
| Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0030-000 | |||
| Darzalex | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0031-000 | |||
| Victoza | liraglutide | Diabetes Mellitus, Type 2 (pediatric) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0032-000 | |||
| Ozurdex | dexamethasone intravitreal implant | Non-infectious uveitis | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0033-000 | |||
| Enhertu | trastuzumab deruxtecan | Metastatic HER2-positive breast cancer | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0035-000 | |||
| Tabrecta | capmatinib | Metastatic non-small cell lung cancer (NSCLC) | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0036-000 | |||
| Sunosi | solriamfetol | Excessive daytime sleepiness | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0039-000 | |||
| Keytruda | pembrolizumab | Non-Small Cell Lung Cancer, neoadjuvant | Active | PC0385-000 | ||||
| Enhertu | trastuzumab deruxtecan | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | PC0367-000 | ||||
| TBC | efanesoctocog alfa | congenital factor VIII deficiency | Active | ST0840-000 | ||||
| TBC | belantamab mafodotin, bortezomib, dexamethasone | Previously treated multiple myeloma | Active | PC0379-000 | ||||
| TBC | belantamab mafodotin, pomalidomide, dexamethasone | Previously treated multiple myeloma | Active | PC0380-000 | ||||
| Ibrance | Palbociclib | Withdrawn | PC0068-000 |
Health Technology Review
Displaying 576 - 590 of 590
Horizon Scan
Displaying 101 - 111 of 111
Projects in Progress
Displaying 26 - 39 of 39
View All Reports
Displaying 1251 - 1275 of 2100
Please scroll or swipe to the right to view the full content.